|
KMID : 0606920220300010090
|
|
Biomolecules & Therapeutics
2022 Volume.30 No. 1 p.90 ~ p.97
|
|
|
Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson’s Disease Models
|
|
Ham Hyeon-Joo
Yeo In-Jun
Jeon Seong-Hee
Lim Jun-Hyung
Yoo Sung-Sik
Son Dong-Ju
Jang Sung-Su
Lee Hak-Sup
Shin Seung-Jin
Han Sang-Bae
Yun Jae-Suk
Hong Jin-Tae
|
|
|
Abstract
|
|
|
|
Recently, increasing evidence suggests that neuroinflammation may be a critical factor in the development of Parkinson’s disease (PD) in addition to the ratio of acetylcholine/dopamine because dopaminergic neurons are particularly vulnerable to inflammatory attack. In this study, we investigated whether botulinum neurotoxin A (BoNT-A) was effective for the treatment of PD through its anti-neuroinflammatory effects and the modulation of acetylcholine and dopamine release. We found that BoNT-A ameliorated MPTP and 6-OHDA-induced PD progression, reduced acetylcholine release, levels of IL-1β, IL-6 and TNF-α as well as GFAP expression, but enhanced dopamine release and tyrosine hydroxylase expression. These results indicated that BoNT-A had beneficial effects on MPTP or 6-OHDA-induced PD-like behavior impairments via its anti-neuroinflammation properties, recovering dopamine, and reducing acetylcholine release.
|
|
|
KEYWORD
|
|
|
Parkinson’s disease, Botulinum toxin A, Anti-neuroinflammation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|